MY200172A - Methods and compositions for treating sleep apnea - Google Patents

Methods and compositions for treating sleep apnea

Info

Publication number
MY200172A
MY200172A MYPI2019006319A MYPI2019006319A MY200172A MY 200172 A MY200172 A MY 200172A MY PI2019006319 A MYPI2019006319 A MY PI2019006319A MY PI2019006319 A MYPI2019006319 A MY PI2019006319A MY 200172 A MY200172 A MY 200172A
Authority
MY
Malaysia
Prior art keywords
compositions
methods
sleep apnea
treating sleep
nri
Prior art date
Application number
MYPI2019006319A
Inventor
D Andrew Wellman
Luigi Taranto-Montemurro
Original Assignee
Brigham & Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63918622&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY200172(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Brigham & Womens Hospital Inc filed Critical Brigham & Womens Hospital Inc
Publication of MY200172A publication Critical patent/MY200172A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Methods and compositions for the treatment of conditions associated with pharyngeal airway muscle collapse while the subject is in a non-fully conscious state, e.g., sleep apnea and snoring, comprising administration of a norepinephrine reuptake inhibitor (NRI) and a muscarinic receptor antagonist. The most illustrative drawing: Figure 1
MYPI2019006319A 2017-04-28 2018-04-26 Methods and compositions for treating sleep apnea MY200172A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762491504P 2017-04-28 2017-04-28
US201762558814P 2017-09-14 2017-09-14
PCT/US2018/029518 WO2018200775A1 (en) 2017-04-28 2018-04-26 Methods and compositions for treating sleep apnea

Publications (1)

Publication Number Publication Date
MY200172A true MY200172A (en) 2023-12-12

Family

ID=63918622

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2019006319A MY200172A (en) 2017-04-28 2018-04-26 Methods and compositions for treating sleep apnea

Country Status (22)

Country Link
US (5) US11123313B2 (en)
EP (1) EP3615016A4 (en)
JP (3) JP7373997B2 (en)
KR (3) KR20250145704A (en)
CN (2) CN110799181A (en)
AU (3) AU2018260666B2 (en)
BR (1) BR112019022483A2 (en)
CA (1) CA3061468A1 (en)
CO (1) CO2019013180A2 (en)
CR (1) CR20190546A (en)
DO (1) DOP2019000274A (en)
EC (1) ECSP19084058A (en)
GE (6) GEAP202416602A (en)
MA (1) MA49069A (en)
MX (2) MX394941B (en)
MY (1) MY200172A (en)
NI (1) NI201900110A (en)
PH (1) PH12019502427A1 (en)
SG (2) SG10202111623TA (en)
UA (1) UA127759C2 (en)
WO (1) WO2018200775A1 (en)
ZA (1) ZA201907158B (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEAP202416602A (en) * 2017-04-28 2024-10-10 Brigham & Womens Hospital Inc Methods and compositions for treating sleep apnea
SI3746126T1 (en) * 2018-01-30 2025-01-31 Apnimed, Inc. (Delaware) Methods and compositions for treating sleep apnea or simple snoring
CN108309261B (en) * 2018-02-11 2020-05-22 西安交通大学 Sudden death early warning method, device and system
US20190381056A1 (en) 2018-06-17 2019-12-19 Axsome Therapeutics, Inc. Compositions for delivery of reboxetine
US20200147093A1 (en) 2018-10-15 2020-05-14 Axsome Therapeutics, Inc. Use of esreboxetine to treat nervous system disorders such as fibromyalgia
US11020402B2 (en) 2018-10-15 2021-06-01 Axsome Therapeutics, Inc. Use of reboxetine to treat narcolepsy
KR20210084481A (en) * 2018-10-31 2021-07-07 애프니메드, 인코포레이티드 (델라웨어) Methods and compositions for the treatment of sleep apnea
EA202192202A1 (en) * 2019-02-08 2021-11-03 Дзе Брихэм Энд Уимен'З Хоспитал, Инк. METHODS AND COMPOSITIONS FOR TREATMENT OF OBSTRUCTIVE APNEA SYNDROME ARISING IN SLEEP
US20220362221A1 (en) * 2019-11-04 2022-11-17 Apnimed, Inc. (Delaware) Combination pharmacological interventions for multiple mechanisms of obstructive sleep apnea
US12448347B2 (en) 2020-05-05 2025-10-21 Apnimed, Inc. (Delaware) Polymorphic forms of (R)-oxybutynin hydrochloride
CN114159568B (en) * 2020-09-11 2025-08-01 北京原基华毅生物科技有限公司 Use of SIK inhibitors for the production of medicaments for the prophylaxis and/or treatment of sleep disorders
RU2757470C1 (en) * 2020-11-19 2021-10-18 Ренат Рашитович Ахмеров Method for treatment of snoring with introduction of trombocytic autologous plasma
US20240075035A1 (en) * 2021-01-14 2024-03-07 Apnimed, Inc. (Delaware) Methods and compositions for treating sleep apnea
CA3210092A1 (en) * 2021-03-04 2022-09-09 Lawrence G. Miller Combination of reboxetine and a muscarinic receptor antagonist (mra) for use in treating sleep apnea
EP4322930A1 (en) * 2021-04-16 2024-02-21 Apnimed, Inc. (Delaware) Combination of a norepinephrine reuptake inhibitor and a cannabinoid for use in treating sleep apnea
IL309251A (en) * 2021-06-17 2024-02-01 Apnimed Inc Delaware Norepinephrine reuptake inhibitors for treating sleep apnea
AU2022340532A1 (en) * 2021-08-31 2024-02-22 Apnimed, Inc. (Delaware) Methods and compositions for treating sleep apnea
CA3259602A1 (en) 2021-12-22 2023-06-29 Bayer Aktiengesellschaft Combination of an .alpha.2-adrenoceptor subtype c (alpha-2c) antagonists with a muscarinic receptor antagonist for the treatment of sleep apnea
KR20240124995A (en) 2021-12-22 2024-08-19 바이엘 악티엔게젤샤프트 A combination of an A2-adrenergic receptor subtype C (alpha-2C) antagonist and a norepinephrine reuptake inhibitor for the treatment of sleep apnea
MX2024007764A (en) * 2021-12-22 2024-07-04 Bayer Ag Combination of a task1/3 channel blocker with a norepinephrine reuptake inhibitor for the treatment of sleep apnea.
US20250302814A1 (en) * 2022-05-13 2025-10-02 Apnimed, Inc. (Delaware) Methods and compositions for treating sleep apnea
US12565478B1 (en) 2025-01-21 2026-03-03 Axsome Therapeutics, Inc. (S)-2-((S)-(2-ethoxyphenoxy)(phenyl)methyl)-4-nitrosomorpholine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU767877B2 (en) 1999-05-20 2003-11-27 Sepracor, Inc. Methods for treatment of asthma using S-oxybutynin
CN1660435A (en) * 2000-02-24 2005-08-31 法玛西雅厄普约翰美国公司 new drug combination
US20060039866A1 (en) * 2004-08-20 2006-02-23 Cypress Bioscience, Inc. Method for treating sleep-related breathing disorders
AU2005319367B2 (en) * 2004-12-20 2012-05-24 Collegium Pharmaceutical, Inc. Pharmaceutical compositions for sleep disorders
EP2672972B1 (en) * 2011-01-28 2020-11-04 Pfantastic Medical Research Institute, LLC Methods for treating obstructive sleep apnea
GEAP202416602A (en) * 2017-04-28 2024-10-10 Brigham & Womens Hospital Inc Methods and compositions for treating sleep apnea
SI3746126T1 (en) * 2018-01-30 2025-01-31 Apnimed, Inc. (Delaware) Methods and compositions for treating sleep apnea or simple snoring

Also Published As

Publication number Publication date
PH12019502427A1 (en) 2020-10-05
NZ758564A (en) 2023-12-22
CR20190546A (en) 2020-04-08
JP2020517719A (en) 2020-06-18
KR20250145704A (en) 2025-10-13
JP7373997B2 (en) 2023-11-06
CO2019013180A2 (en) 2020-02-07
EP3615016A4 (en) 2021-02-24
MA49069A (en) 2020-03-04
KR102682159B1 (en) 2024-07-08
GEAP202416602A (en) 2024-10-10
CA3061468A1 (en) 2018-11-01
JP2025169279A (en) 2025-11-12
BR112019022483A2 (en) 2020-05-12
EP3615016A1 (en) 2020-03-04
CN119185558A (en) 2024-12-27
MX2019012729A (en) 2019-12-19
US11123313B2 (en) 2021-09-21
AU2022241471A1 (en) 2022-10-27
ZA201907158B (en) 2021-09-29
US20240189261A1 (en) 2024-06-13
KR20240042261A (en) 2024-04-01
AU2018260666A1 (en) 2019-11-14
UA127759C2 (en) 2023-12-27
GEAP202316320A (en) 2023-09-11
JP2023139000A (en) 2023-10-03
WO2018200775A1 (en) 2018-11-01
SG10202111623TA (en) 2021-12-30
DOP2019000274A (en) 2019-12-30
GEP20247617B (en) 2024-04-25
GEAP202115226A (en) 2021-12-27
GEP20227387B (en) 2022-06-10
US20240261239A1 (en) 2024-08-08
ECSP19084058A (en) 2020-01-31
AU2025230729A1 (en) 2025-10-02
US20200054583A1 (en) 2020-02-20
US20210401777A1 (en) 2021-12-30
GEP20257788B (en) 2025-08-25
MX2022010349A (en) 2022-09-19
MX394941B (en) 2025-03-24
AU2018260666B2 (en) 2022-07-21
SG11201909973UA (en) 2019-11-28
KR20190140019A (en) 2019-12-18
NI201900110A (en) 2020-03-18
CN110799181A (en) 2020-02-14
US20260007618A1 (en) 2026-01-08

Similar Documents

Publication Publication Date Title
PH12019502427A1 (en) Methods and compositions for treating sleep apnea
MX2025004365A (en) Methods and compositions for treating sleep apnea
MX2024001713A (en) Methods and compositions for treating sleep apnea.
CR10342A (en) INHIBITORS OF THE IAS CHANNELS TASK-1 and TASK-3
GEAP202115256A (en) Diazabicyclic substituted imidazopyrimidines and their use for the treatment of breathing disorders
WO2014120936A3 (en) Treatments for depression and other diseases with a low dose agent
EA201270221A1 (en) TREATMENT OF CROWN DISEASE WITH LACQUINIMODE
PH12019501408A1 (en) Pharmaceutical dosage forms containing task-1 and task-3 channel inhibitors, and the use of same in breathing disorder therapy
PH12019501458A1 (en) Pharmaceutical dosage forms containing task-1 and task-3 channel inhibitors, and the use of same in breathing disorder therapy
MX2024013184A (en) Methods and compositions for treating sleep apnea
JOP20210059A1 (en) ?2-Adrenoceptor subtype C (alpha-2C) antagonists for the treatment of sleep apnea
MX2016008027A (en) Use of laquinimod to delay huntington's disease progression.
MX2021006081A (en) Process for producing pharmaceutical dosage forms containing task-1 and task-3 channel inhibitors, and the use of same in breathing disorder therapy.
SG195150A1 (en) Soft palate support having layered structure and implanting method
MY198201A (en) A Combination Medicament Comprising Phenylephrine And Paracetamol
WO2015103288A3 (en) Oral exercise appliance
EA201992569A1 (en) METHODS AND COMPOSITIONS FOR TREATING APNEA IN SLEEP
NZ758564B2 (en) Methods and compositions for treating sleep apnea
MX2009010805A (en) Methods and compositions comprising desvenlafaxine or duloxetine for treating sleep-related breathing disorders.
MX2024007768A (en) Combination of an î`2-adrenoceptor subtype c (alpha-2c) antagonist with a norepinephrine reuptake inhibitor for the treatment of sleep apnea.
JOP20210113A1 (en) Secondary C (alpha-2C) adrenergic receptor antagonists for the treatment of sleep apnea
EA201990341A1 (en) SUBSTITUTED DIAZAHETEROBICYCLIC COMPOUNDS AND THEIR APPLICATION